Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Stacey Fernandes"'
Autor:
Roberta S. Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey Fernandes, Samantha Shupe, Marissa Terra, Anisha Patel, Matthew S. Davids, Joseph Yu, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Chronic lymphocytic leukemia (CLL) patients have an increased risk of secondary cancers, along with predisposition to CLL in their relatives. We have previously identified germline ATM variants as associated with CLL risk; here, we present their impa
Externí odkaz:
https://doaj.org/article/97a85dd3b87e4eada3214a8ce2c22660
Autor:
Davide Bagnara, Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey Fernandes, Monica Colombo, Stefano Vergani, Andrea N. Mazzarello, Fabio Ghiotto, Silvia Bruno, Fortunato Morabito, Kanti R. Rai, Jonathan E. Kolitz, Jacqueline C. Barrientos, Steven L. Allen, Franco Fais, Matthew D. Scharff, Thomas MacCarthy, Nicholas Chiorazzi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that it very rarely changes clonally over time. Nevertheless, ta
Externí odkaz:
https://doaj.org/article/d46eed87a5ff475f89423d3c64d17572
Autor:
Xuebin Qin, Jennifer R. Brown, Xu Li, Chun Wang, Stacey Fernandes, Weiguo Hu, Lin Wu, Xiaowen Ge
Purpose: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab. Human CD59, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0200b48383669331fb5e536be840f93f
https://doi.org/10.1158/1078-0432.c.6520286
https://doi.org/10.1158/1078-0432.c.6520286
Autor:
Bagnara Davide, Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey Fernandes, Monica Colombo, Stefano Vergani, Andrea N. Mazzarello, Matthew D. Scharff, Thomas MacCarthy, Franco Fais, Nicholas Chiorazzi
Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that it very rarely changes clonally over time. Nevertheless, ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2659::3cc5732658a80ff73492cd7e045f2884
https://zenodo.org/record/5129066
https://zenodo.org/record/5129066
Autor:
Jun Yang, Mollie Jurewicz, Michael R. Clarkson, Joel M. Henderson, Volker Brinkmann, Stacey Fernandes, Mohamed H. Sayegh, Antje Habicht, Xueli Yuan
Publikováno v:
The Journal of Immunology. 176:36-42
FTY720 is a high-affinity agonist at the sphingosine 1-phosphate receptor 1 that prevents lymphocyte egress from lymphoid tissue and prolongs allograft survival in several animal models of solid organ transplantation. In this study we used a recently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ce6dd7537b0dfedb679d7fb0e79bff
https://doi.org/10.4049/jimmunol.176.1.36
https://doi.org/10.4049/jimmunol.176.1.36
Publikováno v:
Molecular Immunology. 45:4156
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3de281f9db8aa2af00ccb9156959ba3a
https://doi.org/10.1016/j.molimm.2008.08.181
https://doi.org/10.1016/j.molimm.2008.08.181